eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
27 hedge funds and large institutions have $13.6M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
13% more funds holding
Funds holding: 24 → 27 (+3)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
60% less capital invested
Capital invested by funds: $33.9M → $13.6M (-$20.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$130K |
| 2 |
WFAG
Wescott Financial Advisory Group
Philadelphia,
Pennsylvania
|
+$43.5K |
| 3 |
Two Sigma Investments
New York
|
+$37K |
| 4 |
MOS
MGO One Seven
Beachwood,
Ohio
|
+$15.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$591K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$68.8K |
| 3 |
VF
Virtu Financial
New York
|
-$22K |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
-$7K |
| 5 |
Morgan Stanley
New York
|
-$980 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MOS
26
MGO One Seven
Beachwood,
Ohio
| $11 | +$15.7K | +803 | New |
|
|
27
Norges Bank
Oslo,
Norway
| – | -$591K | -16,652 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$22K | -627 | Closed |
|
|
PCM
29
Penserra Capital Management
Orinda,
California
| – | -$7K | -204 | Closed |
|
EFTR Hedge Fund Activity: Q3 2022 in Review
27 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q3 2022, worth a combined $13.6M — down 60% from $33.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EFTR positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $130K. The largest seller was Norges Bank, exiting entirely with an estimated $591K sold.
- 27 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q3 2022, up from 24 in Q2 2022.
- Funds reported $13.6M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q3 2022, down 60% quarter-over-quarter.
- 6 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of +3 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q3 2022 was Renaissance Technologies, an estimated $130K added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q3 2022 was Norges Bank, an estimated $591K sold.
Based on aggregated 13F filings for Q3 2022.